Table 3.
Income-specific summary of country-reported rotavirus and diphtheria, pertussis, tetanus (DTP) vaccine coverage estimates, 2016.
| Income Groups for 2016 as Defined by the World Bank |
GAVI Phase IV |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | LICs (n = 19) | LMICs (n = 24) | UMICs (n = 14) | HICs (n = 13) | Total (N = 70) | Eligible (n = 29) | Transitioning (n = 10) | |||||||
| Average Country-Reported Rotavirus Vaccine Coverage | ||||||||||||||
| Dose 1 | 91% | 89% | 89% | 84% | 89% | 91% | 90% | |||||||
| Dose 2–3 | 85% | 83% | 80% | 80% | 82% | 84% | 86% | |||||||
| Drop-out | 8% | 8% | 11% | 6% | 8% | 8% | 4% | |||||||
| Average Country-Reported DTP Vaccine Coverage | ||||||||||||||
| Dose 1 | 95% | 94% | 96% | 98% | 95% | 94% | 94% | |||||||
| Dose 3 | 89% | 88% | 89% | 97% | 90% | 89% | 90% | |||||||
| Drop-out | 6% | 6% | 7% | 1% | 5% | 6% | 4% | |||||||
| Percent Difference between DTP & Rota Vaccine Coverage | ||||||||||||||
| between DTP1 & Rota1 | 19 | 4.0% | 24 | 4.6% | 14 | 7.0% | 13 | 14.0% | 70 | 6.7% | 29 | 3.7% | 10 | 4.4% |
| between DTP3 & Rota2-3 (Rotarix & RotaTeq) | 19 | 5.0% | 24 | 6.3% | 14 | 10.8% | 13 | 17.3% | 70 | 8.9% | 29 | 5.5% | 10 | 4.5% |
| between DTP3 & Rota2 (Rotarix) | 14 | 3.3% | 20 | 2.9% | 11 | 7.2% | 5 | 4.0% | 50 | 4.1% | 23 | 2.9% | 10 | 4.5% |
| between DTP3 & Rota3 (RotaTeq) | 5 | 9.6% | 4 | 23.5% | 3 | 24.1% | 8 | 25.5% | 20 | 20.9% | 6 | 15.3% | — | — |
| National Immunization Program Performance for Rotavirus Vaccine Coverage | ||||||||||||||
| Countries with Good Utilization and Good Access (Drop-out < 10% & Rota1 ≥ 80%) | 14 | 74% | 16 | 67% | 9 | 53% | 9 | 64% | 48 | 65% | 21 | 72% | 7 | 70% |
| Countries with Poor Utilization and Good Access (Drop-out ≥ 10% & Rota1 ≥ 80%) | 2 | 11% | 3 | 13% | 3 | 18% | 1 | 7% | 9 | 12% | 3 | 10% | 1 | 10% |
| Countries with Good Utilization and Poor Access (Drop-out < 10% & Rota1 < 80%) | 0 | 0% | 4 | 17% | 0 | 0% | 1 | 7% | 5 | 7% | 2 | 7% | 2 | 20% |
| Countries with Poor Utilization and Poor Access (Drop-out ≥ 10% & Rota1 < 80%) | 3 | 16% | 1 | 4% | 2 | 12% | 2 | 14% | 8 | 11% | 3 | 10% | 0 | 0% |
Note: Excludes 14 countries (Argentina, Australia, Austria, Ecuador, El Salvador, Iraq, Ireland, Israel, Moldova, Norway, Palau, Paraguay, South Africa, United Kingdom) with missing, incomplete, or inconsistent WHO/UNICEF – Joint Reporting Form (JRF) data for rotavirus vaccine coverages for Rota1 and Rota2-3.
Vaccine coverage for rotavirus vaccine and DTP reported to the WHO/UNICEF – JRF, 2016.
Lower Income Countries (LICs) defined as GNI per capita ≤ US$1,005; Lower-middle Income Countries (LMICs) defined as US$1,006 ≤ GNI per capita ≤ US$3,955; Upper-middle Income Countries (UMICs) defined as US$3,956 ≤ GNI per capita ≤ US$12,235; Higher Income Countries (HICs) defined as GNI per capita > US$12,235.
List of Phase IV countries that receive financial support from Gavi for new vaccine introductions from 2016–2020.
Includes the five (Bhutan, Honduras, Mongolia, Sri Lanka, Ukraine) Phase III (2011-15) Gavi-graduating countries.
Country reported Rotavirus vaccine coverage estimates for dose 1 (Rota1) and either dose 2 or 3 (Rota2-3, depending on the schedule) for countries that have reported introducing the rotavirus vaccine into their National Immunization Programs by December 2016, data collected from the WHO/UNICEF – JRF, 2016.
Drop-out rate between the first and last dose in the vaccine series, calculated using formula: (Coverage first dose – Coverage final dose) / Coverage first dose) × 100.
DTP coverage for dose 1 (DTP1) and dose3 (DTP3) for countries that have reported introducing the rotavirus vaccine into their National Immunization Program by December 2016, data collected from the WHO/UNICEF – JRF, 2016
Percent difference between DTP and Rotavirus Vaccines for the first and last dose of the series. Calculated using formula: [(DTP coverage – Rota coverage) / DTP coverage] × 100.
Performance of delivering the rotavirus vaccine based on four indicators that evaluate service utility and vaccine access based on the calculated rota vaccine drop-out rate and Rota dose 1.